Within Discredited Stem Cell Research, a True Scientific First
By Nicholas Wade,
New York Times
| 08. 03. 2007
The world of stem cell research was set reeling two years ago when its most successful practitioner, the Korean scientist Hwang Woo Suk, was found to have fabricated much of his work. But according to a new post-mortem of his research, he did achieve a scientific first, though not the one he claimed.
Dr. Hwang said he had derived embryonic stem cells from the adult cells of a patient, but the claim was discredited after parts of his research were found to have been faked. A team of Boston scientists has now re-examined stocks of Dr. Hwang's purported embryonic stem cells and arrived at a surprising conclusion: His embryonic stem cells were the product of parthenogenesis, or virgin birth, meaning they were derived from an unfertilized egg.
A team led by Kitai Kim and George Q. Daley of Children's Hospital Boston reports this conclusion today in the journal Cell Stem Cell.
Embryonic stem cells derived through parthenogenesis cannot develop normally, so they are free of ethical objections. The cells could perhaps help treat degenerative diseases in women capable of...
Related Articles
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
